Parkinson's Patients May Benefit From Ketamine, PharmaTher Applies For FDA Fast Track

Specialty pharmaceutical company PharmaTher Holdings PHRRF has submitted a Fast Track Application to the Food and Drug Administration (FDA) for KETARX, a ketamine drug that may help treat levodopa-induced dyskinesia in Parkinson’s disease.

Fast Track designation is for drugs designed to address serious or life-threatening conditions and can expedite development and review. KETARX has previously been found safe, well-tolerated and effective in reducing dyskinesias in Parkinson’s patients in Phase I/II clinical studies.

The results of that study will support PharmaTher’s planned Phase 3 clinical trial, which is being designed in response to FDA recommendations. Ketamine has the potential to treat Parkinson's and other motor disorders.

Latest Startup Investment Opportunities:

Ketamine Brings Hope To Parkinson's Patients

Parkinson’s disease, for which there is no cure, affects up to 10 million people worldwide, with one million in the U.S.

Ketamine, an FDA-approved substance used for anesthetic purposes, may hold promise as a treatment for levodopa-induced dyskinesia, according to a retrospective analysis of patients who received it for pain relief.

Low-dose ketamine may also help treat pain and depression, which are common comorbidities in Parkinson’s patients. PharmaTher owns US Patent No: 11,426,366, which covers the use of ketamine in the treatment of Parkinson’s and other motor disorders.

Photo Credits: Raman Oza on Pixabay.